Pre-market hot trades in US stocks: Shuttle Pharmaceuticals down 8.66% pre-market; Coherent Corp. up 3.48% pre-market

Pre-market Hot Trades in US Stocks Shuttle Pharmaceuticals is down 8.66% in pre-market trading. There have been no significant news recently; trading is active with clear capital flows. Considering the sector and industry trends, the stock shows significant volatility, and the specific reasons need further observation. no_news Coherent Corp. is up 3.48% in pre-market trading. Based on recent key news: On March 31, NVIDIA emphasized the increasing demand for optical communications and co-packaging in future AI data centers at the GTC conference, driving up the stock prices of related companies. The application of indium phosphide has expanded to space, further enhancing market demand for optoelectronic components, benefiting Coherent Corp. On March 30, Taiwanese manufacturers accelerated the restructuring of their material sources to reduce dependence on Chinese suppliers, ensuring a stable supply of high-purity raw materials. Sumitomo Electric has become an important alternative source, boosting market confidence in related companies and driving stock prices up. On March 29, Taiwanese epitaxy factories are actively expanding production to meet AI supply chain demands, with companies like United Microelectronics increasing indium phosphide epitaxy capacity. The market expects related companies to benefit, driving stock prices up. The growth in AI demand is promoting the development of the optical communications industry. Top Gainers in Pre-market US Stocks Cyclerion is up 148.39% in pre-market trading. Based on recent key news: On April 1, Cyclerion Therapeutics announced a merger with Korsana Biosciences, shifting focus to Alzheimer's disease treatment. Post-merger, the company will receive $380 million in private investment, sufficient to support operations until 2029. This news has significantly boosted the stock price. On April 1, Korsana's main experimental drug KRSA-028 is an antibody aimed at slowing the progression of Alzheimer's disease by targeting toxic brain proteins. Early testing is planned for mid-2027, with preliminary patient data to be released later that year. On April 1, the merged company will be led by Korsana's current CEO Jonathan Violin, with Cyclerion shareholders holding approximately 1.5% of the new company, which will trade on NASDAQ under the ticker "KRSA." The biotech industry is focused on Alzheimer's disease treatment. Binah Capital is up 59.22% in pre-market trading. Based on recent news: On March 31, Binah Capital released its Q4 and full-year financial report for 2025. The report showed that the company's performance exceeded market expectations, significantly boosting the stock price. Source: Company announcement On April 1, further details of Binah Capital's financial report were disclosed, showing strong performance in several key business areas, further boosting investor confidence. Source: Company announcement On April 1st, the market reacted positively to Binah Capital's financial report, with a significant increase in trading volume, driving the stock price to continue rising. Source: Market data shows a positive market reaction to the financial report and an increase in trading volume. RenX Enterprises pre-market rose 36.52%. Based on recent key news: On March 30th, RenX Enterprises implemented a reverse stock split to regain compliance. This move aimed to increase the stock price and help the company re-meet Nasdaq's listing requirements, driving the stock price up. On April 1st, RenX Enterprises released its financial performance for the fiscal year ending December 31, 2025. The company disclosed its performance during this period in the financial report, and the positive financial data boosted market confidence, further driving the stock price up. On April 1st, RenX Enterprises filed relevant documents with the SEC to ensure information transparency. This move enhanced investor trust in corporate governance and supported the rise in stock price. The U.S. stock market has been volatile recently, and investors should exercise caution